» Articles » PMID: 38634450

Macrolide Resistance of in Several Regions of China from 2013 to 2019

Abstract

This paper retrospectively analysed the prevalence of macrolide-resistant (MRMP) in some parts of China. Between January 2013 and December 2019, we collected 4,145 respiratory samples, including pharyngeal swabs and alveolar lavage fluid. The highest PCR-positive rate of M. pneumoniae was 74.5% in Beijing, the highest resistance rate was 100% in Shanghai, and Gansu was the lowest with 20%. The highest PCR-positive rate of was 74.5% in 2013, and the highest MRMP was 97.4% in 2019; the PCR-positive rate of for adults in Beijing was 17.9% and the MRMP was 10.48%. Among the children diagnosed with community-acquired pneumonia (CAP), the PCR-positive and macrolide-resistant rates of were both higher in the severe ones. A2063G in domain V of 23S rRNA was the major macrolide-resistant mutation, accounting for more than 90%. The MIC values of all MRMP to erythromycin and azithromycin were ≥ 64 μg/ml, and the MICs of tetracycline and levofloxacin were ≤ 0.5 μg/ml and ≤ 1 μg/ml, respectively. The macrolide resistance varied in different regions and years. Among inpatients, the macrolide-resistant rate was higher in severe pneumonia. A2063G was the common mutation, and we found no resistance to tetracycline and levofloxacin.

Citing Articles

Compassionate Use of Omadacycline in a Down Syndrome Pre-Schooler With Critically Ill Atypical Pneumonia Caused by Macrolide-Resistant Mycoplasma Pneumoniae.

Wu D, Xie F, Wang Y, Jiang X, Zhang G, Zhang H Infect Drug Resist. 2025; 18:391-400.

PMID: 39867285 PMC: 11761846. DOI: 10.2147/IDR.S500982.


An Accuracy Assessment: Responses to Mycoplasma Pneumoniae Pneumonia-Related Questions by Different Artificial Intelligence Tools.

Li S Clin Respir J. 2024; 18(8):e70005.

PMID: 39187912 PMC: 11347124. DOI: 10.1111/crj.70005.

References
1.
Jain S, Self W, Wunderink R, Fakhran S, Balk R, Bramley A . Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med. 2015; 373(5):415-27. PMC: 4728150. DOI: 10.1056/NEJMoa1500245. View

2.
Kuo C, Tsai W, Lee H, Ho T, Huang L, Shen C . The epidemiology, clinical characteristics, and macrolide susceptibility of Mycoplasma pneumoniae pneumonia in children in Southern Taiwan, 2019-2020. J Microbiol Immunol Infect. 2021; 55(4):611-619. DOI: 10.1016/j.jmii.2021.09.010. View

3.
Guo Z, Liu L, Gong J, Han N, He L, Wang W . Molecular features and antimicrobial susceptibility of Mycoplasma pneumoniae isolates from paediatric inpatients in Weihai, China: Characteristics of M. pneumoniae In Weihai. J Glob Antimicrob Resist. 2022; 28:180-184. DOI: 10.1016/j.jgar.2022.01.002. View

4.
. [Guidelines for management of community acquired pneumonia in children(the revised edition of 2013) (II)]. Zhonghua Er Ke Za Zhi. 2014; 51(11):856-62. View

5.
Xue G, Li M, Wang N, Zhao J, Wang B, Ren Z . Comparison of the molecular characteristics of Mycoplasma pneumoniae from children across different regions of China. PLoS One. 2018; 13(8):e0198557. PMC: 6107135. DOI: 10.1371/journal.pone.0198557. View